PCCПолипептидный комплекс хрящевой ткани
What is it?
An animal-cartilage-derived polypeptide complex described in the Russian cartilage research program. It is a mixture containing AED, not a synonym for synthetic Cartalax.
Research context
An animal-cartilage-derived polypeptide complex described in the Russian cartilage research program. It is a mixture containing AED, not a synonym for synthetic Cartalax.
- Working classification
- Tissue-derived polypeptide complex
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —Trial program reported in review; primary trial unrecovered
- Study methods
- —Original reports separated from narrative reviews and patents
- Independent replication
- —Independent replication not established by this collection
- Source access
- —Linked abstracts, analytical papers, reviews and patents; individual scope shown below
- Safety evidence
- —Incomplete assessment; findings do not establish safety for personal use
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Where this preparation fits.
Cartilage & bone: the molecular link
Cartilage polypeptide complex (PCC) → Cartalax / AED
The 2020 UHPLC–MS paper reports AED in cartilage complex. The 2023 review describes PCC as a mixture spanning 75–846 Da.
Clinical boundary
PCC: Phase II was reported in a 2023 review; underlying trial not recovered. AED: a separate 29-patient comparison appears in patent RU2299741C1.
Recover the PCC trial identifier, exact formulation, protocol and results. The patent reports symptom changes without significant radiographic change; neither source establishes cartilage regeneration.
Related preparations
The contextual sources below can concern a related extract, review or molecular link. They are not all direct studies of this profile’s compound.
Linked sources
Explore the research map and unresolved leads ↗
Peptide Regulation of Chondrogenic Stem Cell Differentiation
Linkova N, Khavinson V, Diatlova A, Myakisheva S, Ryzhak G · Int J Mol Sci 24(9):8415. PMID 37176122
Describes the cartilage polypeptide complex PCC and its AED component. The authors reported a Russian Phase II osteoarthritis program in 2023. They connect MSC and fibroblast findings to a cartilage-repair hypothesis.
- Population / setting
- Review of stem-cell differentiation and cartilage research
- What was checked
- Full-text XML checked, including PCC/AED discussion and references 7, 9, 68–70. Trial documents were not supplied by this review.
Limitations & review scope
- The reported trial concerns PCC, not a trial of isolated Cartalax.
- Trial identifier, protocol, enrollment and published human outcomes have not been recovered. Phase II is an attributed 2023 statement, not verified current status.
Source checked 2026-09-29. This is a source-linked record, not a completed evidence review.
Identification of short peptides in the composition of polypeptide complexes isolated from animal organs
I. K. Zhurkovich, N. G. Kovrov, G. A. Ryzhak, E. S. Mironova, V. Kh. Khavinson · Uspekhi Sovremennoi Biologii 140(2):140–148
Reports KED in vessel complex, AED in cartilage, EDG and AEDL in bronchial mucosa, EDR in brain and KEDW in pancreas. This strengthens sequence-level links in the research program.
- Population / setting
- Animal-organ polypeptide complexes analyzed by UHPLC–MS
- What was checked
- Author-hosted Russian PDF: citation and indexed abstract checked; full analytical validation and product-batch equivalence not appraised.
Limitations & review scope
- Molecular detection does not prove identical pharmacology or clinical equivalence.
- The paper’s discussion of clinical work is not an independent clinical trial.
Source checked 2026-09-29. This is a source-linked record, not a completed evidence review.